Novel Methods and Pathways in Cancer Glycobiology Research (eBook)

Karen Abbott, Charles J Dimitroff (Herausgeber)

eBook Download: EPUB

2023 | 1. Auflage
304 Seiten
Elsevier Science (Verlag)
978-0-323-99178-0 (ISBN)

Cancer glycobiology is a blazing hot area of cancer research with aberrant post-translational glycosylations on lipids and proteins considered critical for cancer development and metastasis. The NIH/NCI Alliance of Glycobiologists for Cancer Research is a consortium of (10) tumor glycobiology laboratories funded to investigate how cancer-associated glycans (CAG) impact the development and metastasis of cancer. The hope of this momentous effort is to discover CAGs for use as novel biomarkers to detect early-stage cancer or its aggressive behavior or, alternatively, as novel molecular targets with the promise of a curative approach to cancer therapy. The mission of the 'Alliance' is to study structure and function of CAGs in cancer development and to provide clinically useful biomarkers for detecting cancer early or the potential of metastasis. This charge has stimulated extensive collaborations across US and International institutions to accelerate discovery of glycan-based biomarkers to the forefront of NCI's efforts to diagnose early-stage cancer and provide curative anti-cancer therapies. The main goals of these research efforts are: 1. To identify and study how cancer-associated glycans functionally impact cancer growth and metastasis2. To identify cancer-associated glycans that can serve as biomarkers for the detection or progression of cancer3. To develop cancer-associated glycans as novel therapeutic targets for the treatment and cure of cancer This volume consists of (9) chapters, one from each funded laboratory, that reviews new methods and mechanisms highlighting glycoconjugates and their roles as cancer biomarkers and/or anti-cancer therapeutic targets. - Historical and Novel Glycobiological Biomarkers of Cancer and Disease Progression - Novel Glycobiological Mechanisms Driving Cancer Progression - Novel Methods for Discovering Glycobiological Biomarkers of Cancer

Cancer glycobiology is a blazing hot area of cancer research with aberrant post-translational glycosylations on lipids and proteins considered critical for cancer development and metastasis. The NIH/NCI Alliance of Glycobiologists for Cancer Research is a consortium of (10) tumor glycobiology laboratories funded to investigate how cancer-associated glycans (CAG) impact the development and metastasis of cancer. The hope of this momentous effort is to discover CAGs for use as novel biomarkers to detect early-stage cancer or its aggressive behavior or, alternatively, as novel molecular targets with the promise of a curative approach to cancer therapy. The mission of the 'Alliance' is to study structure and function of CAGs in cancer development and to provide clinically useful biomarkers for detecting cancer early or the potential of metastasis. This charge has stimulated extensive collaborations across US and International institutions to accelerate discovery of glycan-based biomarkers to the forefront of NCI's efforts to diagnose early-stage cancer and provide curative anti-cancer therapies. The main goals of these research efforts are: 1. To identify and study how cancer-associated glycans functionally impact cancer growth and metastasis2. To identify cancer-associated glycans that can serve as biomarkers for the detection or progression of cancer3. To develop cancer-associated glycans as novel therapeutic targets for the treatment and cure of cancerThis volume consists of (9) chapters, one from each funded laboratory, that reviews new methods and mechanisms highlighting glycoconjugates and their roles as cancer biomarkers and/or anti-cancer therapeutic targets. - Historical and Novel Glycobiological Biomarkers of Cancer and Disease Progression- Novel Glycobiological Mechanisms Driving Cancer Progression- Novel Methods for Discovering Glycobiological Biomarkers of Cancer

Erscheint lt. Verlag	23.2.2023
Sprache	englisch
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
	Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie
	Naturwissenschaften ► Biologie ► Zellbiologie
ISBN-10	0-323-99178-5 / 0323991785
ISBN-13	978-0-323-99178-0 / 9780323991780

Haben Sie eine Frage zum Produkt?

EPUB (Adobe DRM)
Größe: 15,6 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Print-Ausgabe

Buch | Hardcover

CHF 207,70